Related Experiment Videos
Safety profile of the triptans.
Stewart J Tepper1, David Millson
1The New England Center for Headache, 778 Long Ridge Rd, Stamford, CT 06902, USA. sjtepper@aol.com
Expert Opinion on Drug Safety
|August 9, 2003
Summary
Triptans, effective migraine and cluster headache treatments, demonstrate an excellent safety profile. Cardiovascular risks, though rare, necessitate contraindication in patients with vascular disease.
Area of Science:
- Pharmacology
- Neurology
- Clinical Medicine
Background:
- Triptans are selective 5-HT(1B/1D) receptor agonists.
- Seven triptans are commercially available worldwide for treating migraine and cluster headaches.
- Sumatriptan has been in clinical use since 1991.
Purpose of the Study:
- To review the safety profile of triptans.
- To discuss the strengths and weaknesses of triptans based on postmarketing studies.
Main Methods:
- Review of postmarketing studies and clinical data.
- Analysis of adverse event reports and drug interaction pathways.
Main Results:
- Triptans exhibit an excellent overall safety profile.
- Cardiovascular events, such as coronary artery narrowing, are the most serious adverse events.
- Triptans are contraindicated in patients with pre-existing vascular disease.
- Other adverse events, including drug-drug interactions and serotonin syndrome, are rare.
Conclusions:
- Triptans are generally safe and effective treatments for migraine and cluster headaches.
- Careful patient selection is crucial, especially regarding cardiovascular risk factors.
- The risk of serotonin syndrome appears minimal based on available data.